Loading…
Clene Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CLNN.
▼ -96.0% over 5Y.
today you would have $31.48▼ -96.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 7 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $5.87 | $5.31 | $6.00 | $20.00 | $82.00 | $216.40 | $209.60 | |
| P/S | 254.2x | 345.7x | 133.3x | 58.9x | 162.6x | 358.0x | 3126.6x | — |
| P/B | 22.2x | — | — | 2.9x | 23.8x | 20.5x | 1888.8x | — |
Companies of similar size in Consumer Defensive, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BRIDBridgford Foods Corp | $6.13 | — | 0.8x | — | -12.67% | $55.64M |
| RYMRYTHM, Inc. | $23.15 | — | 1.3x | — | -10.51% | $49.75M |
| SKILSkillsoft Corp. | $6.93 | — | — | — | — | $62.14M |
| WYHGWing Yip Food Holdings Group Ltd | $4.94 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Company description provided by Yahoo Finance.
| EPS | -$2.65 | -$5.67 | -$9.43 | -$9.20 | -$3.20 | -$22.00 | -$18.60 |
| Profit margin | -8463.59% | -13086.50% | -11520.47% | -7569.42% | -6325.16% | -1347.16% | -9357.77% | — |
| ROE | -646.98% | — | — | -369.71% | -924.25% | -77.32% | -5653.08% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 9.7x |
| 0.3x |
| — |
| 3.74% |
| $62.15M |
| SOWGSow Good Inc. | $3.16 | — | — | — | -82.35% | $63.52M |
| IHiHuman Inc. | $1.25 | 6.0x | 0.4x | — | 7.73% | $63.89M |